Discovery Laboratorie Kauf zu 2,30 $ Ziel 2,55 €

BMO liegt hier ca 25 % im Minus....auf ein Rebound mit ca 10 % zu spekulieren sollte jetzt verkehrt sein.....Nachkauf bei weiterer schwäche nicht ausgeschlossen.



Jäger u Sammler

Hana bio heisst ab morgen "Talon therapeutics" und wird das NDA in 2011 stellen ! Meinst du immer noch ,dass Hana dem Tode geweiht ist ? Ich denke eher DSCO ist zum Verrecken verdammt .....

MFG
Chali

Discovery Labs (DSCO) Stock to Be Delisted from Nasdaq; Will Request Hearing

www.streetinsider.com/Corporate+News/...t+Hearing/6141584.html

December 7, 2010
Leading Proxy Advisory Firms Recommend that Discovery Labs’ Stockholders Vote “FOR” Important Proposals at Annual Meeting of Stockholders

December 7, 2010
Discovery Labs Aerosurf® Improves Lung Function and Reduces Inflammation in a Dose-dependent Fashion in Established Non-Clinical Model of Preterm Respiratory Distress Syndrome

www.discoverylabs.com/home.php

www.mysmartrend.com/news-briefs/...entum-looks-continue-dsco-3

NIH Awards Discovery Labs Fast Track SBIR Grant  to Support Development of Aerosolized KL4 Surfactant
 
 Date : 12/16/2010 @ 7:00AM
Source : GlobeNewswire Inc.
Stock  : Discovery Laboratories, Inc. (DSCO)
 
http://ih.advfn.com/p.php?pid=nmona&article=45679721  
 
Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced  that the Company has been awarded Phase I of a Fast Track Small Business  Innovation Research Grant (SBIR) from the National Institutes of Health  (NIH) to support the development of the Company's program for  aerosolizing KL4 surfactant for neonatal respiratory distress syndrome  (RDS). The Company submitted a proposal, with a total budget of $2.4  million, for the development of the Company's proprietary capillary  aerosol generating (CAG) device technology followed by a Phase 2a  clinical trial of aerosolized KL4 surfactant in preterm infants with or  at risk for RDS. The Phase I grant provides  $580,000 to support development efforts. The Company anticipates the  potential awarding of the Phase II grant, up to an additional $1.8  million, following the conclusion of Phase I activities.
 
 Dr. Robert Segal, Discovery Labs' Senior Vice President and the Grant  Principal Investigator commented, "We are extremely pleased that the NIH  has recognized the importance of our aerosolized KL4 surfactant  technology, which has the potential to significantly improve the  management of preterm infants with or at risk for RDS and make it  possible for many more preterm infants to be treated with surfactant  therapy."
 
RDS is one of the most prevalent medical issues  facing premature infants in the neonatal intensive care unit and is a  condition in which premature infants are born with a lack of natural  lung surfactant and are unable to breathe. Approximately 360,000 low  birth weight premature infants are born annually in the United States  and at risk for RDS. Premature babies with RDS often require  endotracheal intubation and mechanical ventilation. In many cases,  currently available animal-derived surfactants are administered while  the child is intubated. Neonatologists often try to avoid intubation and  mechanical ventilation in preterm infants due to well established  medical risks associated with these procedures. As a result, many  neonatologists reserve intubation for infants with severe respiratory  distress, where the benefits of invasive procedures clearly outweigh the  associated risks.  The Company believes that the neonatal medical  community increasingly recognizes the potential benefits of a synthetic,  peptide-containing surfactant, and a less-invasive method of delivering  surfactant, such as aerosolized KL4 surfactant.  
 
KL4  surfactant is a completely synthetic, peptide-containing surfactant  designed to closely mimic the essential attributes of human lung  surfactant. Discovery Labs is developing aerosolized KL4 surfactant for  delivery in conjunction with non-invasive nasal continuous positive  airway pressure (nCPAP) and other ventilation modalities. Aerosurf®, the  Company's initial aerosolized KL4 surfactant product, holds the promise  to significantly expand the use of surfactant therapy in at-risk  premature infants by potentially providing neonatologists with a means  of administering surfactant without the risks currently associated with  surfactant administration. The Company believes that Aerosurf, if  approved, will allow for a potentially significant increase in the  number of infants who will benefit from surfactant therapy.
 
 Discovery Labs' lead KL4 surfactant product, Surfaxin® for neonatal RDS,  has been previously demonstrated to be generally safe and effective in a  large multi-national Phase 3 clinical program. Surfaxin is the subject  of a Complete Response letter from the U.S. Food and Drug Administration  (FDA) and Discovery Labs expects to submit a complete response to the  FDA in the first quarter of 2011. If approved, Surfaxin would be the  first synthetic, peptide-containing surfactant for commercial use in  neonatal medicine.
 
Surfaxin and Aerosurf are investigational  drugs that have not been approved by the U.S. FDA or any other world  health regulatory authorities.  

Nasdaq 0,2198  $ +13,94% 0,1929

grant

www.bizjournals.com/philadelphia/news/2010/...es-national.html

realtime.bigcharts.com/...tyle=2003&size=1&mocktick=1" style="max-width:560px" alt="" />

...

die waren doch schon fast weg vom Fenster

von Repros Th. (einen kleinen teil) zu 0,29$ zu DSCO umgeschichtet...

haben jetzt fast track bekommen...vor einigen tagen...muss mich mal
updaten...irgendwas köchelt hier...NIH ist ja nicht irgendwer...

mal grob als quelle:

WARRINGTON, Pa., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS). The Company submitted a proposal, with a total budget of $2.4 million, for the development of the Company's proprietary capillary aerosol generating (CAG) device technology followed by a Phase 2a clinical trial...

...aber kann ja ein zweites mal nicht schaden...

... wo der Thread-Titel hervorragend zum aktuellen Wert passt ;-))

nicht so schlecht...+25% in 2h bei umschichtung am abend nehm ich...!!!

da wäre ich mir nicht so sicher denn die NEWS nachbörslich mit dem R/S ist nicht gut wie ich finde.

R/S 1 zu 15  ABER die A/S werden in einem anderen Verhältnis gesplittet und zwar von ALT 380 Millionen zu 50 Millionen.

Kein gutes Zeichen wie ich finde.

Kurs reagiert nachbörslich empfindlich darauf : rt 0,28 Dollar nachbörslich

Discovery Laboratories, Inc. (Nasdaq: DSCO | PowerRating) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Amendment") to effect a 1-for-15 share consolidation, or reverse stock split ("reverse split"), effective at 12:01 a.m. on December 28, 2010 (the "Effective Time"). In addition, the Amendment reduces the number of shares of common stock, par value $0.001 per share, authorized under the Certificate of Incorporation from 380 million to 50 million. Because the Amendment does not reduce the number of authorized shares of common stock in the same proportion as the reverse split, the effect of the Amendment is to increase the number of shares of common stock available for issuance relative to the number of shares issued and outstanding. The stockholders of Discovery Labs approved proposals authorizing the Board of Directors, in its discretion, to implement the reverse split and reduce the number of authorized shares of common stock at the Annual Meeting of Stockholders held on December 21, 2010.

www.tradingmarkets.com/news/press-release/...plit-1389686.html

bei DSCO zu $0,35 - irgendwie ging es mir zu schnell up...- um 21.59 raus...
jetzt weiss ich warum die aktie so flog...machen die einen R/S 1:15... bekannt O.K., aber:

"...Discovery Laboratories, Inc. (Nasdaq: DSCO) announced that they have filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-15 share consolidation, or reverse stock split, effective at 12:01 a.m. on December 28, 2010.

In addition, the Amendment reduces the number of shares of common stock, par value $0.001 per share, authorized under the Certificate of Incorporation from 380 million to 50 million..."

380 mio. zu 50 mio.??? nach adam riese rechne ich bei 1:15 R/S : 380 mio. zu ca. 25 mio.;

sehe ich das richtig oder haben wir hier eine "versteckte KE" von gigantischem ausmaß??

komisch in Posting 87 redest nur von einem perfekten Einstieg.

Ach da war die NEWS ja auch noch nicht raus.

Hat da jemand Probleme zuzugeben mal nen "Fehler" gemacht zu haben?

Na egal gönne jedem sein Gewinn aber manchmal kann man nur schmunzeln.

oder glaubs nicht...

VERKAUF:

400,00  0,35 USD  27.12.2010 21:59:45  
400,00  0,35 USD  27.12.2010 21:59:46  
10.800,00  0,35 USD  27.12.2010 21:59:46  
400,00  0,35 USD  27.12.2010 21:59:47  

aber schmunzeln tu ich auch...

meine zweite umgeschichtete posi: SNSS werde ich vorerst halten!

.

Reverse Split 1:15

Neues Kürzel USA für 20 Tage:DSCOD

www.otcbb.com/asp/quote_module.asp

 

USA 1 Tag